1 Introduction
==============

Recent technological advances have facilitated the production of multiple genome-wide high throughput biological data types, collectively termed 'omics'. These include genomics, transcriptomics, proteomics and many more. Analysis of omics datasets was proven invaluable for basic biological research and for medicine. Until recently, research in computational biology has focused on analyzing a single omic type. While such inquiry provides insights on its own, methods for integrative analysis of multiple omic types may reveal more holistic, systems-level insights.

Omic profiles of large cohorts collected in recent years can help to better characterize human disease, facilitating more personalized treatment of patients. In oncology, analysis of large datasets has led to the discovery of novel cancer subtypes. The classification of tumors into these subtypes is now used in treatment decisions ([@btz058-B21]; [@btz058-B22]). However, these subtypes are usually defined based on a single omic (e.g. gene expression), rather than through an integrative analysis of multiple data types. The large international projects like TCGA ([@btz058-B14]) and ICGC ([@btz058-B37]) now provide multi-omic cohort data, but better methods for their integrated analysis are needed. Novel, improved methods that employ multiple data types for cancer subtyping can allow us to better understand cancer biology, and to suggest more effective and precise therapy ([@btz058-B9]; [@btz058-B24]).

1.1 Multi-Omics clustering approaches
-------------------------------------

There are several approaches to multi-omics clustering (see the reviews by [@btz058-B7]; [@btz058-B23]; [@btz058-B32]). The simplest approach, termed *early integration*, concatenates all omic matrices and applies single-omic clustering on the resulting matrix. LRAcluster ([@btz058-B35]) is an example of such a method, which probabilistically models the distribution of numeric, count and discrete features. Early integration increases the dimensionality of the data, and ignores the different distributions of values in different omics.

*Late integration* methods cluster each omic separately, and then integrate the clustering results, for example using consensus clustering ([@btz058-B17]). PINS ([@btz058-B20]) is a late integration method that defines connectivity matrices as describing the co-clustering of different samples within an omic, and integrates these matrices. Late integration ignores interactions that are weak but consistent across omics.

*Middle integration* approaches build a single model that accounts for all omics. These models include joint dimension reduction of omic matrices and similarity (kernel) based analyses. Dimension reduction approaches include jNMF, MultiNMF ([@btz058-B12]; [@btz058-B38]), iCluster ([@btz058-B25]), and its extensions iClusterPlus and iClusterBayes ([@btz058-B15], [@btz058-B16]). CCA is a classic dimension reduction algorithm ([@btz058-B6]), which linearly projects two omics to a lower dimension such that the correlation between the projections is maximal. MCCA ([@btz058-B34]) generalizes CCA to more than two omics. Because of the high number of features and the complexity of dimension reduction algorithms, feature selection is required. Similarity based methods handle these shortcomings by working with inter-patient-similarities. These methods have improved runtime, and are less reliant on feature selection. Examples are SNF ([@btz058-B31]) and rMKL-LPP ([@btz058-B26]). SNF builds a similarity network of patients per omic, and iteratively updates these networks to increase their similarity until they converge to a single network, which is then partitioned using spectral clustering. rMKL-LPP uses dimension reduction, such that similarities between neighboring samples is maintained in lower dimension. For that purpose, it employs multiple kernel learning, using several different kernels per omic, and providing flexibility in the choice of the kernels. All the middle integration methods above use iterative optimization algorithms, and in some cases guarantee only convergence to local optimum.

To the best of our knowledge, to date, all middle integration methods for multi-omics clustering developed within the bioinformatics community assume full datasets, i.e. data from all omics were measured for each patient. However, in real experimental settings, often for some patients only a subset of the omics were measured. We call these *partial datasets* in the rest of the paper. This phenomenon is already prevalent in existing multi-omic datasets, such as TCGA ([@btz058-B14]), and will increase as cohorts grow. Being able to analyze partial data is of paramount importance, due to the high cost of experiments, and the unequal cost for acquiring data for different omics. Naive solutions like using only those patients with all omics measured or imputation have obvious disadvantages.

A close problem to multi-omics clustering was researched in the machine learning community. In the area of 'multi-view learning' (reviewed in [@btz058-B39]), methods for multi-view clustering actually solve the multi-omic clustering problem. PVC ([@btz058-B11]) is such a method for clustering in the presence of partial data, which is based on joint nonnegative matrix factorization, such that the objective function only considers observed values. This method has not been previously applied on multi-omic data.

1.2 Our contribution
--------------------

We present NEMO (NEighborhood based Multi-Omics clustering), a simple algorithm for multi-omics clustering. NEMO does not require iterative optimization and is faster than prior art. NEMO is inspired and bulids on prior similarity-based multi-omics clustering methods such as SNF and rMKL-LPP. NEMO's novelty lies in its simplicity, and in its support of partial data. Its implementation, as well as code to reproduce the results in this paper, are available in github: <https://github.com/Shamir-Lab/NEMO>.

We evaluated the performance of NEMO by comparing it to a wide range of multi-omics clustering methods on several cancer data types. On full datasets, despite its simplicity, NEMO performed comparably to leading multi-omics clustering algorithms. In order to evaluate performance on partial multi-omic data, we compared NEMO to PVC and to data imputation followed by clustering using several methods. In most tests on synthetic data and on real cancer data, NEMO had clear advantage. Finally, we analyzed NEMO's clustering solution for Acute Myeloid Leukemia, and showed the merit of using multiple omics with partial data.

2 Materials and methods
=======================

NEMO works in three phases. First, an inter-patient similarity matrix is built for each omic. Next, the matrices of different omics are integrated into one matrix. Finally, that network is clustered.

2.1 NEMO -- full omics datasets
-------------------------------

The input to NEMO is a set of data matrices of *n* subjects (samples or patients). Given *L* omics, let *X~l~* denote the data matrix for omic l. *X~l~* has dimensions *p~l~* × *n*, where *p~l~* is the number of features for omic *l*. $P = \Sigma_{l}p_{l}$ is the total number of features.

Denote by *x~li~* the profile of sample *i* in omic *l* (column *i* in *X~l~*). Let *η~li~* denote its *k* nearest neighbors within omic *l*, where Euclidean distance is used to measure profile closeness. For omic *l*, an *n* × *n* similarity matrix *S~l~* is defined as follows: $$S_{l}(i,j) = \frac{1}{\sqrt{2\pi}\sigma_{\mathit{ijl}}}\text{exp}\left( - \frac{\left| \middle| x_{\mathit{li}} - x_{\mathit{lj}} \middle| |^{2} \right.}{2 \cdot \sigma_{\mathit{ijl}}^{2}} \right)$$ where $\sigma_{\mathit{ijl}}^{2}$ is defined by: $$\begin{array}{l}
{\sigma_{\mathit{ijl}}^{2} = \frac{1}{3} \cdot \left( \frac{1}{k}\sum\limits_{r \in \eta_{\mathit{li}}}\left| \middle| x_{\mathit{li}} - x_{\mathit{lr}} \middle| |^{2} \right. + \frac{1}{k}\sum\limits_{r \in \eta_{\mathit{lj}}}\left| \middle| x_{\mathit{lj}} - x_{\mathit{lr}} \middle| |^{2} \right. + \middle| \middle| x_{\mathit{li}} - x_{\mathit{lj}} \middle| |^{2} \right)} \\
\end{array}$$

This similarity measure is based on the radial basis function kernel ([@btz058-B4]). $\sigma_{\mathit{ijl}}^{2}$ is a normalizing factor, which controls for the density of samples by averaging the squared distance of the *i*th and *j*th samples to their nearest neighbors and the squared distance between these two samples ([@btz058-B30], [@btz058-B31]; [@btz058-B36]).

Next, we define the relative similarity matrix, *RS~l~*, for each omic: $$\begin{array}{l}
{RS_{l}(i,j) = \frac{S_{l}(i,j)}{\sum\limits_{r \in \eta_{\mathit{li}}}{S_{l}(i,r)}} \cdot I(j \in \eta_{\mathit{li}}) + \frac{S_{l}(i,j)}{\sum\limits_{r \in \eta_{\mathit{lj}}}{S_{l}(r,j)}} \cdot I(i \in \eta_{\mathit{lj}})} \\
\end{array}$$ where *I* is the indicator function. $RS_{l}(i,j)$ measures the similarity between *i* and *j* relative to *i'*s *k* nearest neighbors and to *j'*s *k* nearest neighbors. Since different omics have different data distributions, the relative similarity is more comparable between omics than the original similarity matrix *S*.

In the next step, NEMO calculates the *n* × *n* average relative similarity matrix *ARS* as: $$\mathit{ARS} = \frac{1}{L}\sum\limits_{l}{RS_{l}}$$

*RS~l~* can be viewed as defining a transition probability between samples, such that the probability to move between samples is proportional to their similarity. Such transition distributions are widely used to describe random walks on graphs ([@btz058-B13]). *ARS* is therefore a mixture of these distributions ([@btz058-B40]).

Given *ARS*, the clusters are calculated by performing spectral clustering on *ARS* ([@btz058-B29]). We use the spectral clustering variant that is based on the eigenvectors of the normalized Laplacian, developed by [@btz058-B19].

To determine the number of clusters, we use a modified eigengap method ([@btz058-B29]). The number of clusters is set to $\mathit{argma}x_{i}(\lambda_{i + 1} - \lambda_{i}) \cdot i$, where *λ* are *ARS* eigenvalues. Intuitively, this objective maintains the idea of the eigengap while encouraging the solution to have a higher number of clusters. This is desired since we observed that often some increase in the number of clusters compared to that prescribed by the eigengap method improved the prognostic value for cancer data. The number of clusters determined by this method is at least as high as the number determined using the eigengap method.

As suggested by [@btz058-B31], we set the number of neighbors in each omic to be $k = \frac{\#\mathit{samples}}{\#\mathit{clusters}}$ in case the number of clusters is known. When the number of clusters is not known, we use $k = \frac{\#\mathit{samples}}{6}$, using 6 as a crude estimate for the number of clusters observed in cancer datasets. We show NEMO's robustness to that parameter.

2.2 NEMO -- partial datasets
----------------------------

NEMO can handle samples that were measured on only a subset of omics. Specifically, we require that each pair of samples has at least one omic on which they were both measured. Note that this holds in particular if there is an omic for which all samples have measurements, which is often the case for gene expression data. Under these conditions, *RS~l~* is computed as in the full-data scenario, but ARS is now only averaged on the observed values. Denote by *JM*(*i*, *j*) the omic types available for both samples. Then: $$\mathit{ARS}(i,j) = \frac{1}{\left| \mathit{JM}(i,j) \right|}\sum\limits_{l \in \mathit{JM}(i,j)}{RS_{l}(i,j)}$$

Note that we require that all samples that have measurements for some omic, have measurements for the same set of features in that omic, such that even in the partial data settings each *X~l~* is a full matrix, albeit with fewer rows. For example, the expression of the same set of genes is measured for all patients with RNA-seq data. When patients have different sets of measured features in the same omic, either intersection of the features or imputation of missing values is required.

On partial datasets, each omic *l* may have a different number of samples $\#\mathit{samples}(l)$. The number *k* of nearest neighbors is chosen per omic. Generalizing the full data setting, for omic *l* we set $k = \frac{\#\mathit{samples}(l)}{6}$.

2.3 Time complexity
-------------------

Computing the distance between a pair of patients in omic *l* takes $O(p_{l})$, so calculating the distance between all patients in all omics takes $O(n^{2} \cdot P)$. The *k* nearest neighbors of each patient and its average distance to them in a specific omic can be computed in time *O*(*n*) per patient ([@btz058-B3]), for a total of $O(n^{2} \cdot L)$. Given the distances, the nearest neighbors, and the average distance to them, each $\sigma_{\mathit{ijl}}^{2}$ can be computed in *O*(*k*) time. Each entry in *RS~l~* is also calculated in *O*(*k*). *ARS* calculation therefore requires $O(n^{2} \cdot P)$, and spectral clustering takes $O(n^{3})$, so the total time is $O(n^{2} \cdot P + n^{3})$.

Other similarity-based methods such as SNF and rMKL-LPP need the same $O(n^{2} \cdot P)$ time to calculate the distances. However, the iterative procedure in both SNF and rMKL-LPP requires $O(n^{3})$ per iteration.

2.4 Clustering assessment
-------------------------

In datasets where the true clustering is known, to gauge the agreement between a clustering solution and the correct cluster structure, we used the adjusted Rand index (ARI) ([@btz058-B8]).

To assess clustering solutions for real cancer samples, we used survival data and clinical parameters reported in TCGA. We used the logrank test for survival ([@btz058-B5]) and enrichment tests for clinical parameters. We used the $\chi^{2}$ test for independence to calculate enrichment of discrete clinical parameters, and Kruskal-Wallis test for numerical parameters. It was previously observed that the $\chi^{2}$ approximation for the statistic of these tests produces biased *P*-values that overestimate the significance ([@btz058-B23]; [@btz058-B28]). In order to better approximate the real *P*-values, we performed permutation tests on the clustering solution, and reported the fraction of permutations for which the test statistic was greater or equal to that of the original clustering solution as the empirical *P*-value. Full details on the permutation testing appear in [@btz058-B23].

3 Results
=========

We applied NEMO in several settings. First, we compared it to nine multi-omics clustering algorithms on ten *full* cancer datasets. We next compared NEMO to several methods on simulated partial data, on multi-view image data and on real cancer datasets with parts of the data artificially removed. Finally, we used NEMO on a real partial cancer dataset.

3.1 Full datasets
-----------------

We applied NEMO to ten TCGA datasets spanning 3168 patients. The datasets are for the following cancer types: Acute Myeloid Leukemia (AML), Breast Invasive Carcinoma (BIC), Colon Adenocarcinoma (COAD), Glioblastoma Multiforme (GBM), Kidney Renal Clear Cell Carcinoma (KIRC), Liver Hepatocellular Carcinoma (LIHC), Lung Squamous Cell Carcinoma (LUSC), Skim Cutaneous Melanoma (SKCM), Ovarian serous cystadenocarcinoma (OV) and Sarcoma (SARC). For each dataset, we analyzed three omics: gene expression, methylation and miRNA expression. When some of the patients lacked measurements for some of the omics, we included only those patients that had data from all omics. We have previously used these datasets to benchmark multi-omics clustering methods ([@btz058-B23]). Datasets sizes varied between 170 and 621 samples. See [@btz058-B23] for full details and preprocessing. Results for the execution of all methods on all datasets appear in [Supplementary](#sup1){ref-type="supplementary-material"}, Tables 1--4. Clustering results for NEMO on all datasets are in [Supplementary File S2](#sup1){ref-type="supplementary-material"}.

We compared NEMO on each dataset to nine different multi-omics clustering methods. As early integration methods we used LRAcluster, and k-means and spectral clustering on the concatenation of all omic matrices. For late integration we used PINS. We used MCCA, MultiNMF and iClusterBayes as joint dimension reduction methods. Finally, SNF and rMKL-LPP represented similarity-based integration. We set *k*, the number of neighbors in NEMO to $k = \frac{\#\mathit{samples}}{6}$. For all methods, we chose the number of clusters in the range 2-15 using the methods recommended by the authors. The results of the nine methods were taken from our benchmark study ([@btz058-B23]), where full details on the execution of all methods are available. (For MCCA, LRAcluster and k-means the results are slightly different, since here we increased the number of k-means repeats they perform in order to increase their stability.)

To assess the clustering solutions we compared the survival curves of different clusters, and performed enrichment analysis on clinical labels (see Section 2). To avoid biases, we chose the same set of clinical parameters for all cancers: age at initial diagnosis, gender and four discrete clinical pathological parameters. These parameters quantify the progression of the tumor (pathologic T), cancer in lymph nodes (pathologic N), metastases (pathologic M) and total progression (pathologic stage). In each cancer type we tested the enrichment of each parameter that was available for it.

[Table 1](#btz058-T1){ref-type="table"}, [Figure 1](#btz058-F1){ref-type="fig"} and [Table 2](#btz058-T2){ref-type="table"} summarize the performance of the ten algorithms on the ten datasets. NEMO found a clustering with significant difference in survival for six out of ten cancer types, while all other methods found at most five. None of the methods found a clustering with significantly different survival for the COAD, LUSC and OV datasets. The *P*-value for KIRC, the only other dataset for which NEMO did not reach significance, was 0.063. NEMO had an average logrank *P*-value of 1.64, second after MCCA (1.75). NEMO found at least one enriched clinical parameter in eight of the ten datasets, the highest number found and tied with spectral clustering, LRACluster, rMKL-LPP, PINS and MCCA. The average number of enriched clinical parameters for NEMO was 1.5, second only to rMKL-LPP with 1.6. Standard deviations across the different datasets for [Figure 1](#btz058-F1){ref-type="fig"} appear in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}.

![Mean performance of the ten algorithms on ten cancer datasets. Y axis: average significance of the difference in survival among clusters (−log10 logrank test's *P*-values). X axis: average number of enriched clinical parameters in the clusters. The dotted lines highlight NEMO\'s performance](btz058f1){#btz058-F1}

###### 

Aggregate statistics of the tested multi-omics clustering methods across ten cancer datasets

                                     K-means     Spectral    LRAcluster    PINS        SNF         rMKL-LPP    MCCA         MultiNMF    iClusterBayes   NEMO
  ---------------------------------- ----------- ----------- ------------- ----------- ----------- ----------- ------------ ----------- --------------- -----------
  Significantly different survival   2           3           5             5           4           4           5            4           2               **6**
  Significant clinical enrichment    7           **8**       **8**         7           7           **8**       **8**        6           5               **8**
  Number of clusters                 2.6 (1.3)   3.3 (2.3)   9.4 (3.8)     4.6 (3.8)   2.8 (0.8)   6.7 (1.6)   10.6 (5.0)   2.2 (0.4)   2.2 (0.4)       4.5 (2.8)
  Runtime (s)                        394 (374)   **4** (2)   3388 (3295)   449 (958)   13 (11)     233 (43)    20 (10)      28 (12)     4298 (1703)     10 (4)

*Note*: First row: number of datasets with significantly different survival. Second row: number of datasets with at least one enriched clinical label. Third row: mean number of clusters. Fourth row: mean runtime. Best performers in each category are marked in bold. The numbers in parentheses are one standard deviation.

###### 

Results of applying the ten algorithms on cancer datasets

  Alg/Cancer   AML         BIC         COAD    GBM         KIRC        LIHC        LUSC    SKCM        OV      SARC        Means         \#sig
  ------------ ----------- ----------- ------- ----------- ----------- ----------- ------- ----------- ------- ----------- ------------- -------
  kmeans       1/**2.9**   0/0.6       0/0     2/**2.3**   0/0.2       1/0.2       1/0.2   2/0.6       1/0.1   2/1.3       1/0.8         7/2
  spectral     1/**1.7**   2/**1.6**   0/0.2   2/**2.2**   0/0.3       2/0.4       2/0.3   2/0.9       1/0.8   2/1.3       1.4/1         8/3
  lracluster   1/**2**     4/**1.3**   0/0.5   1/**1.4**   1/**4.6**   0/0.8       1/0.9   2/**2.7**   1/0.6   2/1         1.3/**1.6**   8/5
  pins         1/1.2       4/1.3       0/0     1/**3.6**   0/**1.8**   2/**2**     1/0.1   2/**2.8**   0/0     2/1.2       0.9/1.3       7/5
  snf          1/**2.9**   2/1         0/0.2   1/**4.1**   1/**2.1**   2/0.2       0/0.6   1/0.6       0/0.2   2/**2.1**   1/**1.4**     7/4
  mkl          1/**2.4**   5/0.6       0/0.5   2/**3**     1/1.1       3/1         0/0.3   1/**2.6**   1/0.1   2/**2.5**   1.6/**1.4**   8/4
  mcca         1/**1.4**   0/**3.2**   1/0.3   2/**1.8**   1/**3.9**   2/0.9       0/0.4   2/**4.3**   1/0.7   2/0.6       1.2/**1.8**   8/5
  nmf          0/1.3       0/1.3       0/0.3   1/**2.1**   1/**1.9**   3/**2.9**   1/0.3   2/**4.5**   0/0.3   2/1.1       1/**1.6**     6/4
  iCluster     0/1         3/0.2       0/0.2   0/1         0/**2**     2/1         2/0.6   3/**4.4**   0/0     2/0.8       1.2/1.1       5/2
  nemo         1/**2.1**   3/**1.4**   0/0.2   1/**2**     1/1.2       3/**3.3**   0/0.4   3/**3.9**   1/0.1   2/**1.8**   1.5/**1.6**   8/6

*Note*: The first number in each cell is the number of significant clinical parameters detected, and the second number is the −log10 *P*-value for survival, with bold numbers indicating significant results. Means are algorithm averages. \#sig is the number of datasets with significant clinical/survival results. We use 0.05 as the threshold for significance.

Compared to the other methods, NEMO tended to choose an intermediate number of clusters per dataset (average 4.5, see [Table 1](#btz058-T1){ref-type="table"}). This number of clusters is small enough so that the clusters will be highly interpretable, but still capture the heterogeneity among cancer subtypes.

NEMO had the the second fastest average runtime after spectral clustering of the concatenated omics matrix. (The same was true for the geometric mean runtime, see [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). All methods except for LRAcluster and iClusterBayes took only a few minutes to run on datasets with hundreds of samples and tens of thousands of features. However, due to NEMO's simple integration step, it was the fastest of all non-trivial integration methods, including other similarity-based methods (SNF and rMKL-LPP). The runtime improvement over SNF was minor for most datasets in the experiment, and was mainly seen in the largest dataset (BRCA), where SNF took 43 s and NEMO 19. For rMKL-LPP, the time reported does not include the similarity computation, as this code was not provided by the authors, but was implemented by us, so its total runtime is higher. Details regarding the hardware used appear in [Supplementary File S1](#sup1){ref-type="supplementary-material"}. We note that since NEMO's integrated network is sparse, its spectral clustering step can be further improved using methods for spectral clustering of sparse graphs (e.g. [@btz058-B10]). This advantage in runtime, and NEMO's improved asymptotic runtime compared to other similarity-based methods (see Section 2) will become more important as the number of patients in medical datasets increases.

3.2 Simulated partial datasets
------------------------------

We next evaluated NEMO's performance on simulated partial datasets. We tested two scenarios. In the first we created two clusters using multivariate normal noise around the clusters' centers, and then created two omics by adding to these data different normal noise for each omic (see [Supplementary File S1](#sup1){ref-type="supplementary-material"}). The simulation is therefore designed such that both omics share the same underlying clustering structure. In the second scenario, we added a third omic that does not distinguish between the clusters. To simulate partial data, we removed the second omic data in an increasing fraction, which we denote *θ*, of randomly chosen samples, for *θ* ranging between 0 and 0.8. We generated 10 different full datasets, and for each dataset and for each value of *θ* we performed ten repeats. Here we report the average ARI between the computed and the correct clustering for each *θ*.

We compared NEMO's performance to PVC, and also to MCCA and rMKL-LPP, the top performers on the full real data. To run PVC on the dataset, we subtracted the minimal observed value from each omic, making all values non-negative, and set PVC's *λ* parameter to 0.01. Since PVC's implementation supports only two omics, we ran it only in the first scenario. To run rMKL-LPP and MCCA on partial data, we completed the missing values using KNN imputation on the concatenated omics matrix. We used KNN imputation since it was shown to perform well in omic data ([@btz058-B27]). We ran the procedure on the concatenated matrix because it allows imputation of values for samples that lack one of the omics, using the similarity of a sample to other samples in other omics, and assuming that the different omics are correlated. As the number of clusters in the simulated data was known to be 2, we set NEMO's parameter *k* to half the number of samples as described in the Section 2. Full details about PVC's execution appear in [Supplementary File S1](#sup1){ref-type="supplementary-material"}. MCCA was applied twice, using two low dimensional representations (See [Supplementary File S1](#sup1){ref-type="supplementary-material"} for details).

[Figure 2](#btz058-F2){ref-type="fig"} shows that NEMO outperformed other methods in both simulations. Furthermore, NEMO performed better on data that were not imputed than on data that were imputed. This shows the advantage of using NEMO directly on partial datasets, rather than performing imputation. In both scenarios, the performance of all methods deteriorated as the fraction of missing data increased. A notable exception was MCCA when using the low dimensional representation of the first omic. We believe this representation was barely affected by the second omic. Interestingly, adding a third omic that contributes no information to the clustering solution decreased the performance, but this decrease was minor for all methods.

![Performance on simulated partial data. We executed the algorithms with an increasing fraction of samples missing data in one of the omics, and compared the resulting clustering to the ground truth using ARI. The left plot uses two omics, and the right plot uses three omics where the third one contains only noise](btz058f2){#btz058-F2}

PVC performed poorly compared to NEMO in the two-omics simulation. In fact, PVC with all data for both omics performed worse than NEMO with 80% missing data in the second omic. We suspect that since PVC is based on linear dimension reduction, it does not capture the spheric structure of the clusters. Since PVC's implementation supports only two omics, we could not test it in the second scenario.

3.3 Image dataset
-----------------

To further test NEMO's performance in a complicated dataset where the true clustering is known, we ran the different methods on Handwritten, an image dataset which contains 2000 images of the digits 0--9, with 200 images of each digit. This dataset is widely used by the machine learning community to benchmark multi-view methods ([@btz058-B39]). We used two 'omics' for this dataset. The first contains 240 pixel averages for windows of size 2 × 3. The second contains 76 Fourier coefficients of the images. For performance reasons, we used only 500 randomly sampled images. We simulated partial data by randomly removing data for half the samples from the second omic. Like in the simulated data, NEMO was compared to the methods with best performance on the full cancer datasets. Data for methods other than NEMO and PVC was imputed using KNN, and the data were clustered assuming ten clusters. We repeated this clustering process ten times, each time selecting at random the samples that were removed in the second omic. [Supplementary Table S6](#sup1){ref-type="supplementary-material"} contains the mean ARI between the obtained clusters and the true clustering. On this dataset, with full data, rMKL-LPP and NEMO were comparable, and they both greatly ourperformed the other methods. On partial data, NEMO was best.

3.4 Partial cancer datasets
---------------------------

We next compared NEMO to other methods on partial cancer datasets, by simulating data loss on the ten full TCGA datasets analyzed above. We tested two scenarios, (i) using three omics for all subtypes, and (ii) using only two omics, to allow comparison with PVC. We randomly sampled a fraction *θ* of the patients and removed their second omic data. The other omic(s) data were kept full. The *θ* values tested were between 0 and 0.7. In all datasets, the first omic was DNA methylation, and the second (from which samples were removed) was gene expression. In the three-omic scenario, the last omic was miRNA expression. We repeated each test five times, and the *P*-values reported here are the geometric averages of the observed *P*-values.

Full details on how each method was executed are in [Supplementary File S1](#sup1){ref-type="supplementary-material"}. We set the number of clusters in PVC to be the same as determined by NEMO, since no method to determine the number of clusters was suggested for PVC. We used survival analysis and enrichment of clinical labels to assess the quality of the clustering solutions. Full results for this analysis are in [Supplementary File S3](#sup1){ref-type="supplementary-material"}.

[Figure 3](#btz058-F3){ref-type="fig"} shows the mean results on three omics across all ten cancer types. NEMO performed best with respect to survival, followed by NEMO with imputation. rMKL-LPP performed best with respect to clinical parameters, followed by NEMO with and without imputation.

![Performance on partial cancer datasets as a function of the fraction of samples missing data in one of the omics. Left: survival analysis. Right: clinical parameters. Results are averages across ten three-omics cancer datasets](btz058f3){#btz058-F3}

Note that in contrast to simulated data, here the performance of the methods did not consistently deteriorate as more data were removed. This is somewhat surprising, as gene expression (the omic that was partially removed) is believed to be the most informative omic. While on average performance across the cancer types was not consistent, we did see a decrease in performance on some of the datasets. The difference between the performance of MCCA for full data here (*θ *= 0) and its previous results ([Fig. 1](#btz058-F1){ref-type="fig"}) is due to the fact that MCCA optimizes its objective with respect to one omic at a time, which makes the solution sensitive to the order of the omics. We also ran MCCA using the original omic order (see [Supplementary Fig. S8](#sup1){ref-type="supplementary-material"}). Still, NEMO outperformed MCCA with respect to survival in all runs except on full data with all three omics (the setting for the original full data experiments).

In the second scenario, out of the datasets that had statistically significant survival results, NEMO was best performer for AML, GBM and SARC, while PVC was best for BIC and SKCM ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). PVC (using the number of clusters determined by NEMO) had best mean survival and clinical enrichment across all datasets ([Supplementary Fig. S6](#sup1){ref-type="supplementary-material"}). This shows the merit of PVC (and of NEMO's method to determine the number of clusters) in datasets with two omics. Interestingly, for both NEMO and PVC, the mean performance across all ten full two-omics datasets was better than the performance of all methods on full three-omics datasets in terms of survival ([Fig. 3](#btz058-F3){ref-type="fig"} and [Supplementary Fig. S6](#sup1){ref-type="supplementary-material"}; see also [Supplementary Fig. S7](#sup1){ref-type="supplementary-material"} for MCCA with the reverse omic order).

Performing imputation increases the runtime of the algorithms. For example, the average time (across 5 runs) to perform imputation for the BIC dataset with methylation and mRNA expression omics, when $\theta = 0.5$, was 560 s. This is a necessary preprocessing step for methods that do not directly support missing data. In contrast, not only do NEMO and PVC not require imputation, but they also run faster as the fraction of missing data increases. The runtime of NEMO on the same two-omic BIC dataset decreased from 42 s with full data to 21 s with $\theta = 0.7$. PVC was slower than NEMO, and its runtime decreased from 92 to 27 s.

3.5 Robustness analysis
-----------------------

We sought to assess NEMO's robustness with respect to the parameter *k*, the number of neighbors, and with respect to the number of clusters. We first tested robustness on the simulated data. We executed NEMO on the three-omic simulated data described previously. We used $k = 10,20,\ldots,200$ and compared the obtained clustering to the known clustering using the Adjusted Rand Index. [Supplementary Figure S9](#sup1){ref-type="supplementary-material"} shows that in that setting, NEMO was highly robust to the choice of *k*, except for low values.

We next performed clustering on the ten cancer datasets using $k = 25,35,\ldots,105$, a range that includes all *k* values we used in the full and partial data analyses. [Supplementary Figure S10](#sup1){ref-type="supplementary-material"} shows the *P*-values for logrank test for each value of *k*. Generally, the performance of NEMO was robust with respect to *k*. In a few cases, such as the GBM, SKCM and SARC datasets, the results varied more depending on *k*. This is partially explained by the different number of clusters NEMO chose for different values of *k* (see [Supplementary Fig. S12](#sup1){ref-type="supplementary-material"}). We conclude that usually changing *k* has little effect on the number of clusters and on the significance. In those cases where significance changed with *k*, it was usually a result of change in the number of clusters chosen (compare [Supplementary Figs S10, S11 and S12](#sup1){ref-type="supplementary-material"}). We next clustered the ten datasets using a number of clusters ranging from 2 to 15. [Supplementary Figures S13 and S14](#sup1){ref-type="supplementary-material"} show the effect of the different number of clusters on the survival analysis and number of enriched clinical parameters. We note that NEMO is less robust to the number of clusters chosen than to *k*.

3.6 Acute myeloid leukemia analysis
-----------------------------------

We applied NEMO to an AML cohort of 197 patients from TCGA. This is a partial dataset, containing 173 patients with gene expression profiles, 194 with methylation and 188 with miRNA profiles. As it is partial, the dataset cannot be directly clustered using other algorithms for multi-omics clustering. To apply these methods, one must limit analysis to a sub-cohort of 170 patients that have full data, or perform imputation. NEMO suggested five clusters for this dataset; their sizes appear in [Figure 4](#btz058-F4){ref-type="fig"}. When plotting survival curves of the clusters ([Fig. 4](#btz058-F4){ref-type="fig"}), we found them to be significantly different (*P*-value = 3.5e−4). The significance was higher than obtained by all other nine clustering methods on the full data subcohort (lowest *P*-value 1.3e−3 using k-means). This shows the higher significance gained from analyzing more samples, including partial data.

![Kaplan-Meier plot for the five clusters obtained by NEMO on the AML partial dataset (logrank *P*-value = 3.5e−4). The number of patients in each cluster is shown in parentheses](btz058f4){#btz058-F4}

We compared the prognostic value of NEMO's clusters to that of the FAB (French-American-British) classification. FAB is a well-accepted clinical classification for AML tumors ([@btz058-B2]), which is based on quantification of blood cells. We performed logrank test using the FAB label as clustering solution, and obtained a *P*-value 5.4e−2, which shows NEMO's favorable prognostic value. Executing NEMO using only a single omic, results for gene expression, methylation and miRNA expression data had logrank *P*-values 3.4e−2, 3.4e−3 and 3.7e−3 respectively. These results demonstrate the improved clustering obtained by NEMO using multi-omic data.

We performed enrichment analysis for each NEMO cluster using the PROMO tool, which allows systematic interrogation of all clinical labels ([@btz058-B18]). In addition to the significantly differential survival, the clusters were found to be enriched in other clinical labels. Cluster 1 had particularly young patients, and showed favorable prognosis. Cluster 2 had poor prognosis, older patients, and was enriched with FAB label 'M0 undifferentiated'. 17 out of 19 patients with label 'M0 undifferentiated' appeared in this cluster. This label corresponds to the undifferentiated acute myeloblastic AML subtype, which is known to have poor prognosis ([@btz058-B1]). Cluster 3 showed favorable prognosis, and was enriched with the M3 FAB label, which corresponds to the acute promyelocytic leukemia (APL) subtype. All 19 patients in this cluster were labeled with M3, and only one patient outside cluster 3 had this label. APL is caused by a translocation between the genes RARA on chromosome 17 and PML on chromosome 15, and is known to have favorable prognosis ([@btz058-B33]). Cluster 4 was enriched with the M5 label, which corresponds to acute monocytic leukemia. Indeed, it was also enriched with a high monocyte count. Finally, cluster 5 was enriched with patients with no known genetic aberrations. All the clustering results and enriched clinical labels are included in [Supplementary Files S4 and S5](#sup1){ref-type="supplementary-material"}.

4 Discussion
============

We presented the NEMO algorithm for multi-omics clustering, and tested it extensively on cancer datasets and in simulation. NEMO is much simpler than existing multi-omics clustering algorithms, has comparable performance on full datasets, improved performance on partial datasets without requiring missing data imputation, and faster execution.

The main insight NEMO uses is that the local neighborhood of each sample best captures its similarity patterns in each omic. We believe that NEMO's performance stems largely from this insight. Previous methods used local similarities, and NEMO suggests that the performance of these methods was largely due to that use, rather than to other steps performed by these algorithms.

NEMO's simplicity makes it more flexible and more easily adapted to different circumstances. It requires only the definition of a distance between two samples within an omic, and can therefore support additional omics, numerical, discrete and ordinal features, as well as more complicated feature types, such as imaging, EMR data and microbiome. In addition to enabling clustering, the network produced by NEMO represents the similarity between samples across all omics, and can thus be used for additional computational tasks. Future work will test the usability of NEMO on discrete data types, and of its output network for tasks other than clustering.

We showed that NEMO can be used to analyze partial multi-omic datasets, i.e. ones in which some samples lack measurements for all omics. Partial datasets are ubiquitous in biology and medicine, and methods that analyze such datasets hold great potential. This challenge is exacerbated by the high cost of high-throughput experiments. While the price of some experiments is decreasing, it is still high for other omics. Methods that analyze partial datasets may affect experimental design and reduce costs, and, as we demonstrated, they can outperform full-data methods applied only to the subset of samples that have all omics. The demand for algorithms that analyze partial datasets is likely to further increase, as more high throughput methods become prevalent, and the number of omics in biomedical datasets increases.

NEMO has several limitations. First, in partial data, each pair of samples must have at least one omic in common. This assumption holds if one omic was measured for all patients, which is often the case for gene expression. Second, the choice of *k*, the number of nearest neighbors, requires further study. NEMO currently chooses the same *k* for all samples, implicitly assuming that all cluster sizes are equal. Choosing different *k* for different samples based on the estimated size of their cluster may further improve NEMO's results. Third, unlike some dimension reduction methods, NEMO does not readily provide insight on feature importance. Given a clustering solution, importance of features to clusters can be computed using differential analysis.

We compared NEMO to PVC in the context of missing data. PVC was developed within the machine learning community for the task of partial multi-view clustering, and has not been applied to omic data previously. Remarkably, on average, in terms of survival analysis, PVC (using the number of clusters of NEMO) outperformed all other methods on the partial cancer datasets with two omics, while NEMO was better on the simulated partial datasets. As PVC is limited to two omics, extension of that NMF-based algorithm to more omics and to include a mechanism for determining the number of clusters is desirable.

In some of the cancer datasets the results obtained using only mRNA expression and DNA methylation were superior to those achieved when also considering miRNA expression. In addition, in some of the datasets we did not observe a significant decrease in performance when removing a fraction of the gene expression data for cancer patients. This phenomenon suggests that multi-omics clustering does not necessarily improve with more omics (see also [@btz058-B23]). A possible explanation is that the different omics are highly correlated, such that additional omics do not add signal. At least for some of the cancer types, this was not the case. Alternatively, it is possible that omics contain contradicting or independent signals, such that removal of data from one omics strengthens the overall structure of the data. While NEMO performed well with an additional omic that contains no signal, future work is needed to deal with omics that contain independent or contradicting signals.

5 Conclusion
============

Clustering cancer patients into subgroups has the potential to define new disease subtypes that can be used for personalized diagnosis and therapy. The increasing diversity of omics data as well as their reduced cost creates an opportunity to use multi-omic data to discover such subgroups. NEMO's simplicity, efficiency and efficacy on both full and partial datasets make it a valuable method for this challenge.

Supplementary Material
======================
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Click here for additional data file.
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